We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

88 hedge funds and large institutions have $461M invested in BioCryst Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

75% more capital invested

Capital invested by funds: $264M → $461M (+$197M)

43% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $7.64M

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

17% more funds holding

Funds holding: 75 → 88 (+13)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
2.54%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
26
Increased
26
Reduced
21
Closed
13
Calls
$10.9M
Puts
$7.64M
Net Calls
+$3.26M
Net Calls Change
+$20K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$68.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.9M
3
State Street
State Street
Massachusetts
+$16.8M
4
CAM
Cormorant Asset Management
Massachusetts
+$9.6M
5
TAM
THB Asset Management
Connecticut
+$3.21M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$8.88M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.23M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.96M
4
TC
TFS Capital
Pennsylvania
-$3.8M
5
SGAM
Smith Group Asset Management
Texas
-$2.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Teacher Retirement System of Texas
76
Teacher Retirement System of Texas
Texas
$18K +$256 +24 +1%
TRCT
77
Tower Research Capital (TRC)
New York
$13K +$4.95K +464 +60%
Bank of Montreal
78
Bank of Montreal
Ontario, Canada
$11K – – –
AIG
79
American International Group
New York
$10.6K -$26.7K -2,500 -71%
QT
80
Quantbot Technologies
New York
$10K +$10.7K +1,000 New
CFA
81
CT Financial Advisors
Pennsylvania
$9.03K +$10.7K +1,000 New
Creative Planning
82
Creative Planning
Kansas
$9K +$53 +5 +0.6%
WA
83
WFG Advisors
Texas
$6K – – –
Dimensional Fund Advisors
84
Dimensional Fund Advisors
Texas
$4K – – –
OC
85
Oakworth Capital
Alabama
$2K – – –
EFSCE
86
Enterprise Financial Services Corp (EFSC)
Missouri
$1K +$1.26K +118 New
Manulife (Manufacturers Life Insurance)
87
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$18 +$1.23K +115 +7%
TC
88
TFS Capital
Pennsylvania
– -$3.8M -499,516 Closed
SGAM
89
Smith Group Asset Management
Texas
– -$2.22M -291,983 Closed
VAM
90
Visium Asset Management
New York
– -$1.78M -234,900 Closed
PA
91
Perceptive Advisors
New York
– -$1.5M -197,500 Closed
Westfield Capital Management
92
Westfield Capital Management
Massachusetts
– -$525K -69,100 Closed
T
93
TradeWorx
New Jersey
– -$284K -37,343 Closed
Two Sigma Investments
94
Two Sigma Investments
New York
– -$281K -37,043 Closed
Invesco
95
Invesco
Georgia
– -$125K -16,446 Closed
DTL
96
Dynamic Technology Lab
Singapore
– -$120K -15,790 Closed
LWM
97
Lyons Wealth Management
Florida
– -$84K -11,000 Closed
ID
98
Integral Derivatives
New York
– -$81K -10,709 Closed
ASN
99
Advisory Services Network
Georgia
– -$59K -7,732 Closed
LTFS
100
Ladenburg Thalmann Financial Services
Florida
– -$8K -1,000 Closed
1 2 3
4
5

BCRX Hedge Fund Activity: Q1 2014 in Review

88 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2014, worth a combined $461M — up 75% from $264M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BCRX positions and 13 closed out — a net gain of 13 holders — while 26 added to existing stakes and 21 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $68.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.88M.

  • 88 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2014, up from 75 in Q4 2013.
  • Funds reported $461M of BioCryst Pharmaceuticals stock for Q1 2014, up 75% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2014 and 13 closed out, a net change of +13 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $68.1M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2014 was Baker Bros. Advisors, an estimated $8.88M sold.

Based on aggregated 13F filings for Q1 2014.